---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-25-000156"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:30:28.108290+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vertex halts VX-264 type 1 diabetes program; expects ~$400M impairment charge

## Summary
- Phase 1/2 trial of VX-264 for type 1 diabetes fails; program will not advance further.
- Vertex expects non-cash impairment charge of ~$400M from VX-264 intangible assets in Q1 and FY 2025.
- Preliminary analysis; Vertex will disclose final impairment results in Q1 2025 Form 10-Q.

## SEC filing metadata
- accession: 0000875320-25-000156
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532025000156/0000875320-25-000156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532025000156/vrtx-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-25-000156
- JSON: https://secwatch.observer/filing/0000875320-25-000156.json
- Plain text: https://secwatch.observer/filing/0000875320-25-000156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.